On June 21, 2025, MetaVia Inc. (MTVA) announced the presentation of preclinical data for DA-1241, the company's novel GPR119 agonist, that showed hepatoprotective effects when administered in combination with Efruxifermin, a fibroblast growth factor 21 (FGF21) analogue, in a mouse model of metabolic dysfunction-associated steatohepatitis (MASH). The results were presented in a poster session at the American Diabetes Association 85th Scientific Sessions. The data showed that 94% of mice receiving the combination therapy achieved a =2-point improvement in the non-alcoholic fatty liver disease (NAFLD) activity score and immunohistochemistry revealed significantly reduced inflammatory and fibrotic gene expression in the liver. These results further support utilizing DA-1241 as part of a combination MASH therapy with an agent that has a complementary mechanism of action.
